Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Recruiting 1Enrolling by invitation 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 6384Neoplasms 5356Prostatic Neoplasms 2964Carcinoma, Non-Small-Cell Lung 2704Colorectal Neoplasms 2674Lung Neoplasms 2262Multiple Myeloma 1656Lymphoma 1598Neoplasm Metastasis 1550Leukemia, Myeloid, Acute 1537Melanoma 1484Pancreatic Neoplasms 1470Ovarian Neoplasms 1420Leukemia 1387Head and Neck Neoplasms 1283Precursor Cell Lymphoblastic Leukemia-Lymphoma 1279Lymphoma, Non-Hodgkin 1226Colonic Neoplasms 1157Carcinoma, Hepatocellular 1141Stomach Neoplasms 1126Leukemia, Lymphocytic, Chronic, B-Cell 1089Brain Neoplasms 1048Rectal Neoplasms 979Lymphoma, Follicular 978Recurrence 971Uterine Cervical Neoplasms 923Glioblastoma 916Carcinoma, Renal Cell 881Lymphoma, Large B-Cell, Diffuse 851Hodgkin Disease 775

Interventions

eprenetapopt 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × MDS × Clear all
NCT03745716 2025-03-18

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Aprea Therapeutics

Phase 3 Completed
154 enrolled 10 charts

MDS

NCT06267898 2024-02-20

Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML

European Society for Blood and Marrow Transplantation

Completed
222 enrolled

MDS

Data powered by HemOnc (CC BY 4.0) Colophon âš¡